|By PR Newswire||
|February 25, 2014 08:20 PM EST||
PASADENA, Calif., Feb. 25, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-drug conjugates using its proprietary monoclonal antibody (mAb) technology platform, today announced the issuance of its first patent, U.S. Patent No. 8,658,774, entitled "Novel Meditopes and Related Meditope-Monoclonal Antibody Delivery Systems, Synthesis and Therapeutic Uses Thereof."
"We view the issuance of this patent, about two years from initial filing, as validation of the novelty of our platform and an important step in our strategy to build and protect a strong and highly differentiated antibody technology," said Stephanie Hsieh, Meditope's president and chief executive officer. "Antibody drug conjugates are an area of significant opportunity in drug development and we look forward to leveraging our unique technology to address the industry's needs."
About Meditope Biosciences, Inc.
Meditope Biosciences is a biotechnology company developing best-in-class antibody-based cancer products. Discovered at City of Hope, a National Cancer Institute designated Comprehensive Cancer Center, Meditope's technology is capable of turning any mAb into a proprietary, site-specific "Lego-like" system that is able to attach and detach drugs to antibodies without the need for chemical conjugation. The result is a memAb (meditope-enabled mAb) product, which is anticipated to be significantly more effective and offer multiple manufacturing advantages compared to existing antibody-drug conjugate technologies. The technology has the potential to advance the antibody market by producing an array of new therapeutic and diagnostic products. More information regarding the company can be found by visiting www.meditope.com.
SOURCE Meditope Biosciences, Inc.
SYS-CON Events announced today that Secure Channels will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. The bedrock of Secure Channels Technology is a uniquely modified and enhanced process based on superencipherment. Superencipherment is the process of encrypting an already encrypted message one or more times, either using the same or a different algorithm.
Sep. 25, 2016 08:15 AM EDT Reads: 1,440
Sep. 25, 2016 08:00 AM EDT Reads: 1,479
Sep. 25, 2016 08:00 AM EDT Reads: 1,487
Sep. 25, 2016 08:00 AM EDT Reads: 1,660
Sep. 25, 2016 07:30 AM EDT Reads: 1,751
Sep. 25, 2016 06:30 AM EDT Reads: 2,797
Sep. 25, 2016 05:45 AM EDT Reads: 1,605
Sep. 25, 2016 05:30 AM EDT Reads: 981
Sep. 25, 2016 04:45 AM EDT Reads: 1,503
Sep. 25, 2016 04:15 AM EDT Reads: 1,682
Sep. 25, 2016 04:15 AM EDT Reads: 1,381
Sep. 25, 2016 03:15 AM EDT Reads: 3,352
Sep. 25, 2016 02:45 AM EDT Reads: 1,715
Sep. 25, 2016 02:45 AM EDT Reads: 879
Sep. 25, 2016 02:15 AM EDT Reads: 1,215